News Lilly forges a $415m ALS alliance with UK biotech Alchemab Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients.
R&D Turning drug development on its head In episode 98 of the pharmaphorum podcast , host Jonah Comstock and Alchemab CEO Young Kwon discuss innovative new routes to drug discovery
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face